Affimed N.V.
LSE: 0HL9.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Wolfgang Fischer
- Employees
- 76
- Headquarters
- Mannheim, Germany
- IPO year
- 2018
- Market cap
- $3.1K
- Website
- https://www.affimed.com
Loading 0HL9…
Loading profile data…Frequently asked questions about 0HL9
What does Affimed N.V. (0HL9.L) do?
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
Where does 0HL9.L trade?
Affimed N.V. (0HL9.L) trades on the London Stock Exchange.
What sector is 0HL9.L in?
Affimed N.V. (0HL9.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Affimed N.V.?
Wolfgang Fischer is the chief executive officer of Affimed N.V. (0HL9.L).
Where is Affimed N.V. headquartered?
Affimed N.V. is headquartered in Germany.
Does 0HL9.L pay a dividend?
Affimed N.V. (0HL9.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HL9.L go public?
Affimed N.V. (0HL9.L) completed its initial public offering in 2018.